Zacks.com on MSN2h
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a ...
Hosted on MSN1d
Do Wall Street Analysts Like Moderna Stock?
Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...
MRNA, PFE, BNTX: Pharma Stocks Fall as RFK Jr. Set to Become U.S. Health Secretary
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
Moderna: The Good News Isn't Enough
Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...
Forbes1mon
What’s Behind The Recent Rise In MRNA Stock?
The company’s latest RSV vaccine is yet to show promising sales. This has weighed on MRNA stock, down 52% since early 2024. Even if we look at a slightly longer period, the changes in MRNA stock ...
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Yahoo Finance8d
Why MRNA Stock Is Retreating
which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison's Statement on Potential Cancer Vaccines Last week, Oracle Chairman Larry Ellison asserted that AI ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...